Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 57.88M shares rose 0.7% year over year, behind the +1.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.7% toward the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
57.88M+0.1% QoQ
Last fiscal yearDec 2025
57.49M+1.1% YoY
LTMJun 2026
57.95M+1.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.7%——
1 year+1.1%——
3-year CAGR-1.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
57.49M USD
Year-over-year change
+1.1%
4-year CAGR
-0.0%

Weighted Avg Shares vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 weighted avg shares of 57.95M shares is the 2nd highest of the 4 companies compared; the peer median is 27.3M shares.
  • Its year-over-year change of +1.3% is the lowest of 3, against a peer median of +147.0%.
  • Over three fiscal years its annual growth of -1.0% compares with a peer median of +30.1%.
HRMY Competitors Peer median
Weighted Avg Shares for HRMY and competitors
Company Period LTM YoY 3-year CAGR
CMPSCOMPASS Pathways plcLTM Mar 202698.1M +33.3%+30.1%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202657.95M +1.3%-1.0%
NERVMinerva Neurosciences, Inc.LTM Jun 202627.3M +260.6%+16.6%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
APMDApnimed, Inc.—— ——
Peer median (excluding HRMY) 27.3M+147.0%+30.1%

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue305.44M437.86M582.02M714.73M868.45M
Cost of Revenue55.52M83.48M121.24M156.82M198.34M
Gross Profit249.92M354.37M460.79M557.92M670.11M
Gross Margin81.8%80.9%79.2%78.1%77.2%
Research & Development30.37M70.89M76.06M145.83M189.59M
Selling, General & Admin132.03M163.3M192.69M221.27M272.05M
Operating Expenses162.39M234.19M268.76M367.09M461.64M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
EBITDA80.46M146.87M221.51M233.41M255.05M
EBITDA Margin26.3%33.5%38.1%32.7%29.4%
Operating Income87.53M120.19M192.03M190.83M208.47M
Operating Margin28.7%27.4%33.0%26.7%24.0%
Interest Income224K3.13M14.73M18.54M21.92M
Interest Expense24.19M18.8M23.76M17.5M14.65M
Other Income / Expenses(50.1M)(15.5M)(18.63M)978K6.6M
Income Before Tax37.43M104.69M173.4M191.8M215.06M
Pre-Tax Margin12.3%23.9%29.8%26.8%24.8%
Income Tax Expense2.83M(76.78M)44.54M46.31M56.38M
Net Income34.6M181.47M128.85M145.49M158.69M
Net Margin11.3%41.4%22.1%20.4%18.3%
EPS (Basic)0.603.072.172.562.76
EPS (Diluted)0.582.972.132.512.71
Weighted Avg Shares57.53M59.17M59.47M56.89M57.49M
Weighted Avg Shares (Diluted)59.21M61.1M60.37M57.87M58.54M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.